ES2570630T3 - Vacunas de Globo H y relacionadas contra el cáncer con nuevos adyuvantes glicolipídicos - Google Patents

Vacunas de Globo H y relacionadas contra el cáncer con nuevos adyuvantes glicolipídicos

Info

Publication number
ES2570630T3
ES2570630T3 ES09789075T ES09789075T ES2570630T3 ES 2570630 T3 ES2570630 T3 ES 2570630T3 ES 09789075 T ES09789075 T ES 09789075T ES 09789075 T ES09789075 T ES 09789075T ES 2570630 T3 ES2570630 T3 ES 2570630T3
Authority
ES
Spain
Prior art keywords
balloon
cancer
related vaccines
glycolipid adjuvants
ssea
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09789075T
Other languages
English (en)
Inventor
Chi-Huey Wong
Chung-Yi Wu
Alice Yu
John Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Academia Sinica
Original Assignee
Academia Sinica
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Academia Sinica filed Critical Academia Sinica
Application granted granted Critical
Publication of ES2570630T3 publication Critical patent/ES2570630T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/001173—Globo-H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Una composición inmunogénica que comprende: (a) un glicano que consiste esencialmente en Globo H, el antígeno-3 específico de la etapa embrionaria (SSEA-3. Gb5) y el antígeno-4 específico de la etapa embrionaria (SSEA-4, sialil-Gb5), Bb4, o un fragmento inmunogénico del mismo, en el que el glicano que se conjuga con una proteína portadora es el material 197 que presenta reacción cruzada con la toxina de la difteria (DT-CRM197) o el toxoide de la difteria, a través de un enlazante; y (b) un adyuvante de α-galactosil-ceramida (α-GalCer).
ES09789075T 2008-06-16 2009-08-06 Vacunas de Globo H y relacionadas contra el cáncer con nuevos adyuvantes glicolipídicos Active ES2570630T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6196808P 2008-06-16 2008-06-16
US12/485,546 US20090317411A1 (en) 2008-06-16 2009-06-16 Compositions for inducing immune responses specific to globo h and ssea3 and uses thereof in cancer treatment
PCT/US2009/004519 WO2010005598A1 (en) 2008-06-16 2009-08-06 Globo h and related anti-cancer vaccines with novel glycolipid adjuvants

Publications (1)

Publication Number Publication Date
ES2570630T3 true ES2570630T3 (es) 2016-05-19

Family

ID=41431519

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09789075T Active ES2570630T3 (es) 2008-06-16 2009-08-06 Vacunas de Globo H y relacionadas contra el cáncer con nuevos adyuvantes glicolipídicos

Country Status (11)

Country Link
US (4) US20090317411A1 (es)
EP (2) EP2303286A4 (es)
JP (4) JP2011524375A (es)
KR (1) KR20110031949A (es)
CN (1) CN102065868A (es)
AU (2) AU2009268937A1 (es)
CA (2) CA2728344A1 (es)
ES (1) ES2570630T3 (es)
MX (2) MX2010013932A (es)
NZ (1) NZ590140A (es)
WO (2) WO2010005735A2 (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
CA2723197C (en) 2008-05-02 2017-09-19 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
KR101324109B1 (ko) * 2008-06-16 2013-10-31 아카데미아 시니카 Ｇｌｏｂｏ ｈ 및 그의 절편들에 대한 항체의 양에 따른 암 진단방법
KR20110031949A (ko) * 2008-06-16 2011-03-29 아카데미아 시니카 Ｇｌｏｂｏ ｈ 및 ｓｓｅａ3에 특이적인 면역 반응을 유도하기 위한 조성물 및 암 치료에서의 이의 용도
US8680020B2 (en) 2008-07-15 2014-03-25 Academia Sinica Glycan arrays on PTFE-like aluminum coated glass slides and related methods
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
WO2011130332A1 (en) 2010-04-12 2011-10-20 Academia Sinica Glycan arrays for high throughput screening of viruses
CN107261129A (zh) * 2010-05-03 2017-10-20 财团法人生物技术开发中心 用作疫苗的多糖与去毒大肠杆菌(e. coli)不耐热肠毒素(lt)的偶联
CA2801922A1 (en) * 2010-06-11 2011-12-15 Sloan-Kettering Institute For Cancer Research Multivalent glycopeptide constructs and uses thereof
US9504702B2 (en) 2010-08-05 2016-11-29 Seattle Genetics, Inc. Methods of inhibition of protein fucosylation in vivo using fucose analogs
GB201013767D0 (en) * 2010-08-17 2010-09-29 Isis Innovation Identification of ligands and their use
US20120288525A1 (en) 2011-05-11 2012-11-15 Chakravarty Sumana Pharmaceutical compositions comprising attenuated plasmodium sporozoites and glycolipid adjuvants
JP6187939B2 (ja) * 2012-03-08 2017-08-30 学校法人産業医科大学 がんの悪性度の試験方法、ならびに多能性を有する造腫瘍細胞およびその調製方法
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
WO2014031498A1 (en) 2012-08-18 2014-02-27 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
CA2883168A1 (en) 2012-08-21 2014-02-27 Academia Sinica Benzocyclooctyne compounds and uses thereof
MX363385B (es) 2012-08-23 2019-03-20 Seattle Genetics Inc Métodos para el tratamiento de enfermedad de células falciformes y otras condiciones inflamatorias.
AU2014203977B2 (en) * 2013-01-04 2016-11-17 Obi Pharma, Inc. Vaccines with higher carbohydrate antigen density and novel saponin adjuvant
WO2014178195A1 (ja) 2013-05-02 2014-11-06 独立行政法人産業技術総合研究所 糖鎖抗原の免疫誘導剤
WO2014210397A1 (en) * 2013-06-26 2014-12-31 Academia Sinica Rm2 antigens and use thereof
US9981030B2 (en) 2013-06-27 2018-05-29 Academia Sinica Glycan conjugates and use thereof
GB201313352D0 (en) 2013-07-26 2013-09-11 Isis Innovation Identification of peptide ligands
CA2923579C (en) 2013-09-06 2023-09-05 Academia Sinica Human inkt cell activation using glycolipids with altered glycosyl groups
NZ714555A (en) 2013-09-17 2020-03-27 Obi Pharma Inc Compositions of a carbohydrate vaccine for inducing immune responses and uses thereof in cancer treatment
JP2017507118A (ja) 2014-01-16 2017-03-16 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ がんの処置および検出のための組成物および方法
WO2016114819A1 (en) * 2015-01-16 2016-07-21 Academia Sinica Compositions and methods for treatment and detection of cancers
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
CN106456766B (zh) * 2014-03-19 2020-03-10 台湾基督长老教会马偕医疗财团法人马偕纪念医院 抗免疫原性糖肽的抗体、包含其的组合物及其用途
CN106415244B (zh) 2014-03-27 2020-04-24 中央研究院 反应性标记化合物及其用途
RU2016138744A (ru) * 2014-04-10 2018-05-11 Оби Фарма Инк. Антитела, фармацевтические композиции и их применения
WO2015184004A1 (en) 2014-05-27 2015-12-03 Academia Sinica Anti-cd20 glycoantibodies and uses thereof
EP3149045B1 (en) 2014-05-27 2023-01-18 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
JP7062361B2 (ja) 2014-05-27 2022-05-06 アカデミア シニカ 抗ｈｅｒ２糖操作抗体群およびその使用
CA2950433A1 (en) 2014-05-28 2015-12-03 Academia Sinica Anti-tnf-alpha glycoantibodies and uses thereof
GB201414021D0 (en) * 2014-08-07 2014-09-24 Nascient Ltd Biological materials and uses thereof
MX2017002333A (es) * 2014-08-22 2017-08-28 Academia Sinica Conjugados novedosos de glicano y uso de los mismos.
EP3191500A4 (en) * 2014-09-08 2018-04-11 Academia Sinica HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS
KR102679516B1 (ko) * 2014-09-15 2024-07-02 오비아이 파머 인코퍼레이티드 면역원성/치료적 당접합체 조성물 및 그의 용도
US20170348414A1 (en) * 2014-09-15 2017-12-07 Wayne State University Novel synthetic anticancer, antifungal, and antibacterial vaccines
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
EP3248013B1 (en) * 2015-01-24 2020-07-15 Academia Sinica Cancer markers and methods of use thereof
EP3248005B1 (en) * 2015-01-24 2020-12-09 Academia Sinica Novel glycan conjugates and methods of use thereof
DK3250590T3 (da) 2015-01-30 2021-10-18 Academia Sinica Sammensætninger og fremgangsmåder, der vedrører universelle glycoformer, til øget anti-SSEA4-antistofeffektivitet
CN105067813A (zh) * 2015-07-23 2015-11-18 丁晓昆 一种快速检测t-合酶活性的方法
CN108350605A (zh) * 2015-09-04 2018-07-31 台湾浩鼎生技股份有限公司 聚糖阵列以及使用方法
CA3016170A1 (en) 2016-03-08 2017-09-14 Academia Sinica Methods for modular synthesis of n-glycans and arrays thereof
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
CA3019560A1 (en) 2016-03-29 2017-10-05 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
US11583577B2 (en) * 2016-04-22 2023-02-21 Obi Pharma, Inc. Cancer immunotherapy by immune activation or immune modulation via Globo series antigens
US11642400B2 (en) * 2016-07-27 2023-05-09 Obi Pharma, Inc. Immunogenic/therapeutic glycan compositions and uses thereof
EP3491026A4 (en) * 2016-07-29 2020-07-29 OBI Pharma, Inc. HUMAN ANTIBODIES, PHARMACEUTICAL COMPOSITIONS AND METHODS
KR102588027B1 (ko) 2016-08-22 2023-10-12 초 파마 인크. 항체, 결합 단편 및 사용 방법
TW201825522A (zh) * 2016-09-23 2018-07-16 張志隆 抗-globo h 抗體
TWI767959B (zh) 2016-11-21 2022-06-21 台灣浩鼎生技股份有限公司 共軛生物分子、醫藥組成物及方法
TWI842710B (zh) * 2018-05-11 2024-05-21 台灣浩鼎生技股份有限公司 預測人體免疫反應的方法
US11203645B2 (en) 2018-06-27 2021-12-21 Obi Pharma, Inc. Glycosynthase variants for glycoprotein engineering and methods of use
JP7319362B2 (ja) 2018-11-02 2023-08-01 シーメンス・ヘルスケア・ダイアグノスティックス・インコーポレイテッド マクロフィリン結合医薬アッセイに使用するための結合競合剤およびその使用方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6544952B1 (en) * 1994-03-15 2003-04-08 Sloan-Kettering Institute For Cancer Research Synthesis of glycoconjugates of the globo-H epitope and uses thereof
US20040126381A1 (en) * 1996-04-23 2004-07-01 Xin-Xing Gu Intranasal immunization with detoxified lipooligosaccharide from nontypeable haemophilus influenzae or moraxella
EP0996455B1 (en) * 1997-04-16 2009-12-16 Sloan-Kettering Institute For Cancer Research Alpha-o-linked glycoconjugates with clustered (2,6)-st epitopes, methods of preparation and uses thereof
WO2001065261A1 (en) * 2000-02-29 2001-09-07 Sloan-Kettering Institute For Cancer Research Affinity matrix bearing tumor-associated antigens
GB0108364D0 (en) * 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
GB0024200D0 (en) * 2000-10-03 2000-11-15 Smithkline Beecham Sa Component vaccine
EP1458242A4 (en) 2001-07-06 2006-06-07 Sloan Kettering Inst Cancer COMPREHENSIVE CONJUGATED VACCINE AGAINST CANCER
WO2003009812A2 (en) * 2001-07-25 2003-02-06 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
US7132101B2 (en) * 2002-02-27 2006-11-07 Duquesne University Of The Holy Ghost Compositions and methods for eliciting an immune response to gram-negative bacterial infections
WO2004028475A2 (en) * 2002-09-27 2004-04-08 Biomira, Inc. Glycosylceramide analogues
US20060035267A1 (en) * 2003-04-09 2006-02-16 Livingston Philip O Optimal polyvalent vaccine for cancer
GB0313916D0 (en) * 2003-06-16 2003-07-23 Glaxosmithkline Biolog Sa Vaccine composition
WO2006068758A2 (en) * 2004-11-19 2006-06-29 The Scripps Research Institute Detection, prevention and treatment of breast cancer
GB0428394D0 (en) 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
US7923013B2 (en) 2004-12-28 2011-04-12 The Rockefeller University Glycolipids and analogues thereof as antigens for NKT cells
JP5090928B2 (ja) 2004-12-28 2012-12-05 ザ ロックフェラー ユニバーシティ Ｎｋｔ細胞に対する抗原としての糖脂質及びその類似体
KR100764678B1 (ko) * 2005-07-13 2007-10-09 재단법인서울대학교산학협력재단 알파-갈락토실세라마이드를 아쥬반트로 포함하는 비강투여용 백신 조성물
JP5564672B2 (ja) * 2006-06-30 2014-07-30 ザ スクリプス リサーチ インスティテュート アジュバント及びその使用方法
CN101225383B (zh) * 2007-01-15 2011-10-12 燕秋 用于抑制LeY糖抗原合成的岩藻糖基转移酶Ⅰ和Ⅳ的RNA干涉序列及重组干涉质粒
US9603922B2 (en) * 2007-02-21 2017-03-28 Vaccinex, Inc. Modulation of NKT cell activity with antigen-loaded CD1d molecules
GB0703369D0 (en) * 2007-02-21 2007-03-28 Health Prot Agency Compositions Comprising Capsular Polysaccharides and Their Use as Vaccines
WO2008128207A1 (en) * 2007-04-13 2008-10-23 Academia Sinica Alpha-galactosyl ceramide analogs and their use as immunotherapies
CA2688268A1 (en) * 2007-06-04 2008-12-11 Novartis Ag Formulation of meningitis vaccines
KR20110031949A (ko) * 2008-06-16 2011-03-29 아카데미아 시니카 Ｇｌｏｂｏ ｈ 및 ｓｓｅａ3에 특이적인 면역 반응을 유도하기 위한 조성물 및 암 치료에서의 이의 용도
US8383767B2 (en) * 2008-06-27 2013-02-26 Academia Sinica Immunogenic protein carrier containing an antigen presenting cell binding domain and a cysteine-rich domain
US7928077B2 (en) * 2008-07-11 2011-04-19 Academia Sinica Alpha-galactosyl ceramide analogs and their use as immunotherapies

Also Published As

Publication number Publication date
MX2010013932A (es) 2013-03-01
JP2011524417A (ja) 2011-09-01
CA2728344A1 (en) 2010-01-14
EP2303286A2 (en) 2011-04-06
AU2009268937A1 (en) 2010-01-14
KR20110031949A (ko) 2011-03-29
US8268969B2 (en) 2012-09-18
AU2009269127A1 (en) 2010-01-14
CA2728341C (en) 2019-07-02
MX350230B (es) 2017-08-30
NZ590140A (en) 2012-07-27
EP2303286A4 (en) 2011-12-28
EP2310047A1 (en) 2011-04-20
JP2014144958A (ja) 2014-08-14
CA2728341A1 (en) 2010-01-14
US20150273034A1 (en) 2015-10-01
US20090317411A1 (en) 2009-12-24
US9028836B2 (en) 2015-05-12
AU2009269127B2 (en) 2013-12-05
US20120328646A1 (en) 2012-12-27
WO2010005598A1 (en) 2010-01-14
WO2010005735A2 (en) 2010-01-14
EP2310047B1 (en) 2016-03-30
US20100136042A1 (en) 2010-06-03
JP2016020363A (ja) 2016-02-04
WO2010005735A3 (en) 2010-03-18
JP5795655B2 (ja) 2015-10-14
JP2011524375A (ja) 2011-09-01
CN102065868A (zh) 2011-05-18
JP5628158B2 (ja) 2014-11-19
US9603913B2 (en) 2017-03-28
JP6151319B2 (ja) 2017-06-21

Similar Documents

Publication Publication Date Title
ES2570630T3 (es) Vacunas de Globo H y relacionadas contra el cáncer con nuevos adyuvantes glicolipídicos
MX2022014850A (es) Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina transportadora.
MX2022009927A (es) Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina transportadora.
PE20212335A1 (es) Composiciones inmunogenicas que comprenden antigenos sacaridos capsulares conjugados y usos de los mismos
MX2023009362A (es) Vacunas de conjugado multivalente con polisacaridos de conjugado bivalente o multivalente que proporcionan inmunogenicidad y avidez mejoradas.
MX2022009928A (es) Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina transportadora.
AR075851A1 (es) Vacunas anti-cancer dirigidas contra celulas presentadoras de antigenos
AR092897A1 (es) Composiciones inmunogenicas
RS54349B1 (en) VACCINE CONTAINING STREPTOCOCCUS PNEUMONIAE Capsular POLYSACCHARIDE CONJUGATES
PE20240927A1 (es) Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados, kits que las comprenden y sus usos
AR082952A1 (es) Variantes no lipidadas de antigenos orf2086 de neisseria meningitidis
RU2015131033A (ru) Вакцины с повышенной плотностью размещения углеводного антигена и новый сапониновый адъювант
AR100859A1 (es) Polisacáridos y sus usos
CL2007003780A1 (es) Metodo para preparar conjugados que comprenden polisacaridos de strptococcus pneumoniae y una proteina carrier
PE20071058A1 (es) Vacuna de streptococcus pneumoniae
CO6480925A2 (es) Composiciones inmunogénicas de antígenos de staphylococcus aures referencia cruzada a las solicitudes relacionadas.
PE20070163A1 (es) Composicion inmunogenica de conjugados de sacaridos de n. meningitidis
CY1110002T1 (el) Τροποποιημενη πρωτεϊνη ηεχον αδενοϊου και χρησεις αυτης
AR052541A1 (es) Vacunas de glicoconjugados que contiene peptidoglicina
CO6382137A2 (es) Oligonucleótidos inmunoestimuladores
CO6241131A2 (es) Vacuna
CL2011000914A1 (es) Vacuna combinada estable completamente liquida que comprende antigenos difterico, tetanico, pertusico acelular, de haemophilus influenzae, y de virus de poliomielitis en donde el antigeno se haemophilus influenzae no esta sustancialmente absorbido sobre ningun adyuvante; y proceso de fabricacion.
CL2012000744A1 (es) Proceso para preparar un conjugado de polisacáridos capsulares tipo 5 o tipo 8 de s. aureus y una molécula transportadora; conjugado de polisacáridos; y composición inmunogénica que lo comprende.
CR10143A (es) Antígenos de ácido des-n-acetil-siálico, anticuerpos para los mismos y métodos de uso en la terapia del cáncer
CO2021007863A2 (es) Vacuna conjugada polisacárido-proteína neumocócica multivalente